Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech
Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018 Capital Markets and Public M&A

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB

 Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
October 08, 2026

Vinge has advised Folksam Group in connection with two investments in infrastructure funds

 Vinge has advised Folksam Group in connection with two investments totalling SEK 7.2 billion in infrastructure funds managed by Copenhagen Infrastructure Partners and Arjun Infrastructure Partners, respectively.
October 08, 2026